BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Deaths reported in Lebanon as Israel and Hezbollah exchange attacks - 2People who talk with their hands seem more clear and persuasive – new research
- 3A Texas GOP congressman is retiring. Trump just endorsed his identical twin to replace him.
- 4Surveys of 6 Hot Savvy Beds
- 5Astronomer captures 2 meteors slamming into the moon (video)
- Who plays Moana in the live-action remake? What to know about Catherine Lagaʻaia.
- Find the Historical backdrop of Common liberties: Advancing Equity and Equity Around the world
- Exploring the Main Year of Life as a parent: Individual Encounters
- Photos: Presidential turkey pardons — a look back
- New science points to 4 distinct types of autism
- Can humans have babies in space? It may be harder than expected
- JW Marriott Tokyo: an elegant retreat amid whirlwind of the city
- Smuggler who called migrants 'chickens' jailed
- Choosing Moving Styles for Your Restroom Redesign
